Navigating HER2+ Breast Cancer Treatment: Expert Perspectives on Patient Selection and Treatment Sequencing
Panelists highlighted evolving personalized treatment strategies in HER2-positive metastatic breast cancer—spanning maintenance therapy innovations, frontline and later-line sequencing with agents like trastuzumab deruxtecan and tucatinib, management of CNS metastases and toxicities such as interstitial lung disease, and the critical role of multidisciplinary care and clinical trials in optimizing patient outcomes and quality of life throughout complex, prolonged disease courses.
EP. 1: Current Treatment Approaches in HER2+ Metastatic Breast Cancer
June 17th 2025Panelists discussed how evolving strategies in HER2-positive metastatic breast cancer are shifting toward more personalized maintenance approaches, including the integration of CDK4/6 inhibitors and endocrine therapy, with growing interest in chemotherapy-free options for select patients.
EP. 2: Optimizing Maintenance Therapy After First-Line Treatment in HER2+ Metastatic Breast Cancer
June 17th 2025Panelists discussed how maintenance therapy in HER2-positive metastatic breast cancer is evolving beyond traditional dual antibody approaches, with emerging strategies incorporating targeted agents like tucatinib and endocrine therapy to personalize care and potentially delay central nervous system progression.
